Skip Ribbon Commands
Skip to main content
Skip over global navigation links
U.S. Department of Health and Human Services

COVID-19 Monoclonal Antibody Therapeutics

 State/territory-coordinated   Distribution of Monoclonal Antibody   Therapeutics by Week. Learn More.
New and Notable: COVID-19 mAbs Announcements



COVID-19 monoclonal antibody therapeutics (mAb) can be used to treat eligible non-hospitalized patients who have tested positive for COVID-19 and have mild to moderate symptoms. These treatments mimic your immune system’s response to SARS-CoV-2 (the infection that causes COVID-19) and are available to eligible patients 12 years and older with a high risk of progressing to severe forms of COVID-19 or being hospitalized. REGEN-COV can be administered through IV or subcutaneous injection.

HHS/ASPR has purchased supplies of COVID-19 mAb products and we are working with state and territorial health departments as well as national healthcare and medical organizations and associations to get the treatments into the hands of healthcare providers quickly, with a focus on areas of the country hardest hit by the pandemic.


The Federal Response: Clinical Implementation Guide   Weekly update calls State/Territory-Coordinated Distribution



Resources for Professionals

Resources for Administration Sites Resources for Healthcare and EMS Professionals Communications ToolkitPromising Practices for Healthcare Professionals



Products Purchased by the US Government

REGEN-COV Bam/estSotrovimabBamlanivimabCOMBAT COVID


  • This page last reviewed: November 22, 2021